IGI Logo

Glenmark Pharmaceuticals is currently trading at Rs. 2183.30, up by 1.85 points or 0.08% from its previous closing of Rs. 2181.45 on the BSE.

The scrip opened at Rs. 2185.30 and has touched a high and low of Rs. 2215.00 and Rs. 2181.00 respectively. So far 6145 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2471.05 on 29-Apr-2026 and a 52 week low of Rs. 1515.55 on 05-Jun-2025.

Last one week high and low of the scrip stood at Rs. 2,439.70 and Rs. 2144.40 respectively. The current market cap of the company is Rs. 62329.69 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.67% and 13.68% respectively.

Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc.

According to IQVIA sales data for the 12-month period ending April 2026, the Vimpat Injection market achieved annual sales of around $15.2 million.